A new independent
1126 page research with title 'Type 2 Diabetes - Pipeline Review, H2 2017’guarantees you
will remain better informed than your competition. The study covers
geographic analysis that includes regions and important players/vendors such as
Adocia SAS, AFFiRiS AG, Allergan Plc, AntriaBio Inc, Aphios Corp, etc.
Type 2 diabetes is a chronic condition and is the most common form of diabetes.
High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
Request a sample report @ https://www.htfmarketreport.com/sample-report/806324-type-2-diabetes-pipeline-review-1
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 2, 23, 66, 68, 3, 234, 77 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 68 and 20 molecules, respectively.
Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/806324-type-2-diabetes-pipeline-review-1
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Place a Purchase Order for Type 2 Diabetes Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=806324
Companies mentioned in the Report
4P Therapeutics LLC
Addex Therapeutics Ltd
Adocia SAS
Aegis Therapeutics LLC
AFFiRiS AG
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
AntriaBio Inc
Aphios Corp
Araim Pharmaceuticals Inc
Arecor Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
AusBio Ltd
Avadel Pharmaceuticals Plc
Bayer AG
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioLingus AG
BioRestorative Therapies Inc
Biozeus
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Therapeutics Inc
Braasch Biotech LLC
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Cardax Inc
Carmot Therapeutics Inc
Celon Pharma SA
Center Laboratories Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
CohBar Inc
Concenter BioPharma Silkim Ltd
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
CSL Ltd
CureDM Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dance Biopharm Inc
Delpor Inc
Diabetology (Products) Ltd
DiaMedica Therapeutics Inc
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
Dong-A Socio Holdings Co Ltd
Elcelyx Therapeutics Inc
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd
Genexine Inc
Genfit SA
Genmedica Therapeutics SL
Genovate Biotechnology Co LTD
Geropharm LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
HitGen LTD
Hyundai Pharmaceutical Co Ltd
Immuron Ltd
Inflazome Ltd
Innovative Targeting Solutions Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Intas Pharmaceuticals Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Intrexon Corp
Ionis Pharmaceuticals Inc
Islet Sciences Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadimastem Ltd
Kadmon Corp LLC
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
Ligand Pharmaceuticals Inc
LipimetiX Development Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Magnus Life Ltd
MannKind Corp
Medesis Pharma SA
Medestea Research & Production SpA
MedImmune LLC
Medlab Clinical Ltd
Melior Discovery Inc
Mellitech SAS
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Mitsubishi Chemical Holdings Corp
Mitsubishi Tanabe Pharma Corp
Naia Ltd
Neurimmune Holding AG
Neurocrine Biosciences Inc
NGM Biopharmaceuticals Inc
Nordic Bioscience A/S
Novapeutics LLC
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
Pila Pharma AB
Poxel SA
Prometheon Pharma LLC
ProMetic Life Sciences Inc
Prothena Corp Plc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
ReCyte Therapeutics Inc
reMYND NV
Renova Therapeutics Inc
Reset Therapeutics Inc
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co Ltd
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Sevion Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sprint Bioscience AB
Sumitomo Dainippon Pharma Co Ltd
Suzuken Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
Teijin Pharma Ltd
The Medicines Company
Theracos Inc
Thermalin Diabetes LLC
Tiziana Life Sciences Plc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
TTY Biopharm Company Ltd
Twoxar Inc
Uni-Bio Science Group Ltd
ViaCyte Inc
Vichem Chemie Research Ltd
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
XBiotech Inc
XL-protein GmbH
XOMA Corp
XuanZhu Pharma Co Ltd
Yabao Pharmaceutical Group Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zafgen Inc
Zealand Pharma AS
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/806324-type-2-diabetes-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
Type 2 diabetes is a chronic condition and is the most common form of diabetes.
High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
Request a sample report @ https://www.htfmarketreport.com/sample-report/806324-type-2-diabetes-pipeline-review-1
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 2, 23, 66, 68, 3, 234, 77 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 68 and 20 molecules, respectively.
Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/806324-type-2-diabetes-pipeline-review-1
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Place a Purchase Order for Type 2 Diabetes Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=806324
Companies mentioned in the Report
4P Therapeutics LLC
Addex Therapeutics Ltd
Adocia SAS
Aegis Therapeutics LLC
AFFiRiS AG
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
AntriaBio Inc
Aphios Corp
Araim Pharmaceuticals Inc
Arecor Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
AusBio Ltd
Avadel Pharmaceuticals Plc
Bayer AG
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioLingus AG
BioRestorative Therapies Inc
Biozeus
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Therapeutics Inc
Braasch Biotech LLC
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Cardax Inc
Carmot Therapeutics Inc
Celon Pharma SA
Center Laboratories Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
CohBar Inc
Concenter BioPharma Silkim Ltd
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
CSL Ltd
CureDM Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dance Biopharm Inc
Delpor Inc
Diabetology (Products) Ltd
DiaMedica Therapeutics Inc
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
Dong-A Socio Holdings Co Ltd
Elcelyx Therapeutics Inc
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd
Genexine Inc
Genfit SA
Genmedica Therapeutics SL
Genovate Biotechnology Co LTD
Geropharm LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
HitGen LTD
Hyundai Pharmaceutical Co Ltd
Immuron Ltd
Inflazome Ltd
Innovative Targeting Solutions Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Intas Pharmaceuticals Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Intrexon Corp
Ionis Pharmaceuticals Inc
Islet Sciences Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadimastem Ltd
Kadmon Corp LLC
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
Ligand Pharmaceuticals Inc
LipimetiX Development Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Magnus Life Ltd
MannKind Corp
Medesis Pharma SA
Medestea Research & Production SpA
MedImmune LLC
Medlab Clinical Ltd
Melior Discovery Inc
Mellitech SAS
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Mitsubishi Chemical Holdings Corp
Mitsubishi Tanabe Pharma Corp
Naia Ltd
Neurimmune Holding AG
Neurocrine Biosciences Inc
NGM Biopharmaceuticals Inc
Nordic Bioscience A/S
Novapeutics LLC
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
Pila Pharma AB
Poxel SA
Prometheon Pharma LLC
ProMetic Life Sciences Inc
Prothena Corp Plc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
ReCyte Therapeutics Inc
reMYND NV
Renova Therapeutics Inc
Reset Therapeutics Inc
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co Ltd
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Sevion Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sprint Bioscience AB
Sumitomo Dainippon Pharma Co Ltd
Suzuken Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
Teijin Pharma Ltd
The Medicines Company
Theracos Inc
Thermalin Diabetes LLC
Tiziana Life Sciences Plc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
TTY Biopharm Company Ltd
Twoxar Inc
Uni-Bio Science Group Ltd
ViaCyte Inc
Vichem Chemie Research Ltd
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
XBiotech Inc
XL-protein GmbH
XOMA Corp
XuanZhu Pharma Co Ltd
Yabao Pharmaceutical Group Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zafgen Inc
Zealand Pharma AS
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/806324-type-2-diabetes-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218
No comments:
Post a Comment